The allogeneic cell therapy from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.
Allogeneic Cell Therapy Market, 2024 report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.
Market Size –
The allogenic cell therapy market size has grown rapidly in recent years. It will grow from $0.97 billion in 2023 to $1.08 billion in 2024 at a compound annual growth rate (CAGR) of 11.3%. The growth in the historic period can be attributed to an increased focus on tailoring donor cell selection and genetic modifications, increased population, increase in the global burden of chronic diseases, increased awareness, and increase in the number of collaborations for biosimilar development.
The allogenic cell therapy market size is expected to see rapid growth in the next few years. It will grow to $1.67 billion in 2028 at a compound annual growth rate (CAGR) of 11.6%. The growth in the forecast period can be attributed to the increasing need for advanced medical treatments, growing demand for novel allogeneic cell therapies, rising number of clinical trials, growing patient population contributions, and rising income levels. Major trends in the forecast period include technology advancements, partnerships, big companies collaborating with others, merger and acquisitions, new product launch.
Order your report now for swift delivery @
https://www.thebusinessresearchcompany.com/report/allogeneic-cell-therapy-global-market-report
Scope Of Allogeneic Cell Therapy Market
The Business Research Company’s reports encompass a wide range of information, including:
1. Market Size (Historic and Forecast): Analysis of the market’s historical performance and projections for future growth.
2. Drivers: Examination of the key factors propelling market growth.
3. Trends: Identification of emerging trends and patterns shaping the market landscape.
4. Key Segments: Breakdown of the market into its primary segments and their respective performance.
5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.
6. Macro Economic Factors: Assessment of broader economic elements impacting the market.
Allogeneic Cell Therapy Market Overview
Market Drivers –
The increasing prevalence of chronic diseases is expected to drive the growth of the allogeneic cell therapy market. Chronic disease is a long-lasting condition that typically requires ongoing medical attention and can limit daily activities or quality of life. The prevalence of chronic disease is due to altered habits, inheritance, and exposure to chemicals, toxins, and pollutants in the air. Allogeneic cell therapy holds significant potential for treating a wide range of chronic diseases by utilizing healthy cells from a donor to repair, replace, or modulate the dysfunctional cells or tissues in the recipient. For instance, in January 2023, according to the National Center for Biotechnology Information (NCBI), a US-based medicine library, the number of people aged 50 and above who suffer from one or more chronic illnesses is expected to increase by 99.5% by 2050, from 71.52 million in 2020 to 142.66 million. Therefore, the increased prevalence of chronic diseases drives the growth of the allogeneic cell therapy market.
Market Trends –
Major companies operating in the allogeneic cell therapy market are focusing on developing innovative solutions, such as cell processing platforms, to strengthen their position in the market. Cell processing platforms are systems and technologies used to prepare and manipulate cells for therapeutic applications, encompassing isolation, purification, expansion, modification, and quality control to ensure cells are suitable for clinical use. For instance, in March 2024, Getinge, a Sweden-based healthcare company, partnered with CellRev, a UK-based biotechnology company, to launch Livit ACE, a platform for continuous cell processing (Adherent Cell Expansion). This innovative platform integrates advanced automation and bioprocessing technologies, significantly enhancing the efficiency and scalability of cell production. Its unique features include state-of-the-art cell isolation and purification systems that ensure high cell purity and viability, robust expansion capabilities to produce large quantities of therapeutic cells, sophisticated genetic modification tools for precise cell engineering, and rigorous quality control measures to guarantee the safety and efficacy of the cell products.
The allogeneic cell therapy market covered in this report is segmented –
1) By Type: Stem Cell Therapies, Non-Stem Cell Therapies
2) By Therapeutic Area: Hematological Disorders, Dermatological Disorders, Other Therapeutic Area
3) By End User: Hospitals, Specialty Clinics, Research Organizations
Get an inside scoop of the allogeneic cell therapy market, Request now for Sample Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=15976&type=smp
Regional Insights –
North America was the largest region in the allogeneic cell therapy market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the allogeneic cell therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Key Companies –
Major companies operating in the allogeneic cell therapy market are Novartis AG, Bristol Myers Squibb Company, Takeda Pharmaceutical Company Limited, Bluebird Bio Inc., Poseida Therapeutics Inc., Fate Therapeutics Inc., Fortress Biotech Inc., Sorrento Therapeutics Inc., Eureka Therapeutics Inc., Juno Therapeutics Inc., Adaptimmune Therapeutics plc, Cellectis SA, TrakCel Ltd., Promab Biotechnologies Inc., Ziopharm Oncology Inc., Allogene Therapeutics Inc., Century Therapeutics Inc., Autolus Therapeutics plc, Bellicum Pharmaceuticals Inc., Minerva Biotechnologies Corporation, Celyad SA, TILT Biotherapeutics Ltd., CRISPR Therapeutics AG
Table of Contents
1. Executive Summary
2. Allogeneic Cell Therapy Market Report Structure
3. Allogeneic Cell Therapy Market Trends And Strategies
4. Allogeneic Cell Therapy Market – Macro Economic Scenario
5. Allogeneic Cell Therapy Market Size And Growth
…..
27. Allogeneic Cell Therapy Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
